Scholarlink

Introduction <p>Gastric cancer (GC) incidence and mortality have declined globally in age-standardised terms, but crude case numbers remain substantial in ageing Western populations. Intestinal-type (ITGC) and diffuse-type gastric cancer (DTGC), including signet-ring cell carcinoma (SRCGC), differ markedly in biology, prognosis, and therapeutic options. To date, no Irish population-based study has reported recent GC trends stratified by histological subtype.</p> Methods <p>This retrospective, observational study included all incident GCs diagnosed in Ireland between 2007 and 2021, identified from the National Cancer Registry Ireland (NCRI). Variables analysed included year of diagnosis, age, sex, histology, and stage (available 2014–2019). Comparative analyses used χ² testing, and multinomial regression was applied to model adenocarcinoma not otherwise specified (NOS) cases. Crude incidence rates were calculated using Central Statistics Office population denominators.</p> Results <p>A total of 6,708 GCs were diagnosed (mean 447 cases/year). Crude incidence rates averaged 9.6 per 100,000 population. Histological breakdown showed 18% ITGC, 5% DTGC, 15% SRCGC, and 57% NOS. Regression modelling indicated that ~ 50% of NOS resembled ITGC, 38% SRCGC, and 12% DTGC. DTGC/SRCGC disproportionately affected younger and male patients and presented more often at stage IV (38–42%) than ITGC (27%). Extrapolated to NCRI projections for 2045 (1,294 cases annually), this equates to ~ 175 stage IV ITGC cases potentially eligible for oligometastatic interventions, and ~ 300–350 stage IV DTGC/SRCGC cases requiring peritoneal-directed therapies.</p> Conclusions <p>Crude case numbers, histological subtype, and stage at presentation will determine Ireland’s future GC healthcare burden. Accurate subtyping and staging will be essential for planning advanced multimodal services.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gastric cancer recent epidemiological trends in a low-risk Western population: a National Cancer Registry cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Eoghan Burke,
  • Patricia Harkins,
  • Sarah Fenn,
  • Mayilone Arumugasamy

摘要

Introduction

Gastric cancer (GC) incidence and mortality have declined globally in age-standardised terms, but crude case numbers remain substantial in ageing Western populations. Intestinal-type (ITGC) and diffuse-type gastric cancer (DTGC), including signet-ring cell carcinoma (SRCGC), differ markedly in biology, prognosis, and therapeutic options. To date, no Irish population-based study has reported recent GC trends stratified by histological subtype.

Methods

This retrospective, observational study included all incident GCs diagnosed in Ireland between 2007 and 2021, identified from the National Cancer Registry Ireland (NCRI). Variables analysed included year of diagnosis, age, sex, histology, and stage (available 2014–2019). Comparative analyses used χ² testing, and multinomial regression was applied to model adenocarcinoma not otherwise specified (NOS) cases. Crude incidence rates were calculated using Central Statistics Office population denominators.

Results

A total of 6,708 GCs were diagnosed (mean 447 cases/year). Crude incidence rates averaged 9.6 per 100,000 population. Histological breakdown showed 18% ITGC, 5% DTGC, 15% SRCGC, and 57% NOS. Regression modelling indicated that ~ 50% of NOS resembled ITGC, 38% SRCGC, and 12% DTGC. DTGC/SRCGC disproportionately affected younger and male patients and presented more often at stage IV (38–42%) than ITGC (27%). Extrapolated to NCRI projections for 2045 (1,294 cases annually), this equates to ~ 175 stage IV ITGC cases potentially eligible for oligometastatic interventions, and ~ 300–350 stage IV DTGC/SRCGC cases requiring peritoneal-directed therapies.

Conclusions

Crude case numbers, histological subtype, and stage at presentation will determine Ireland’s future GC healthcare burden. Accurate subtyping and staging will be essential for planning advanced multimodal services.